



## Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination

S. Lambert-Niclot, C. Allavena, M. Grude, P. Flandre, S. Sayon, E. André, M. Wirden, A. Rodallec, T. Jovelin, C. Katlama, et al.

### ► To cite this version:

S. Lambert-Niclot, C. Allavena, M. Grude, P. Flandre, S. Sayon, et al.. Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination. *Journal of Antimicrobial Chemotherapy*, 2016, 10.1093/jac/dkw146 . hal-01332106

**HAL Id: hal-01332106**

**<https://hal.sorbonne-universite.fr/hal-01332106>**

Submitted on 15 Jun 2016

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Usefulness of an HIV DNA Resistance Genotypic Test in Patients Who Are Candidates  
for a Switch to the rilpivirine/emtricitabine/tenofovir Combination

S Lambert-Niclot<sup>1\*</sup>, C Allavena<sup>2</sup>, M Grude<sup>1</sup>, P Flandre<sup>1</sup>, S Sayon<sup>1</sup>, E Andre<sup>3</sup>, M Wirden<sup>1</sup>, A Rodallec<sup>3</sup>, T Jovelin<sup>2</sup>, C Katlama<sup>4</sup>, V Calvez<sup>1</sup>, F Raffi<sup>2</sup>, AG Marcelin<sup>1</sup>.

<sup>1</sup> Sorbonne Universités, UPMC Univ Paris 06, UMR\_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, Paris, F-75013, France

<sup>2</sup> Infectious Diseases Department, University Hospital of Nantes, Nantes, France

<sup>3</sup> Virology, University Hospital of Nantes, Nantes, France

<sup>4</sup> Sorbonne Universités, UPMC Univ Paris 06, UMR\_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Service de maladies Infectieuses, Paris, F-75013, France

Keywords :antiretroviral resistance, DNA genotype, rilpivirine

Running title: Switch to the RPV/TDF/FTC and DNA genotype

\*Corresponding author: Sidonie LAMBERT-NICLOT

Mailing address: Department of Virology  
Pitié-Salpêtrière Hospital  
83 Boulevard de l'Hôpital, 75013 Paris, France

Phone: 33142177401, Fax: 33142177411

Email: [sidonie.lambert@psl.aphp.fr](mailto:sidonie.lambert@psl.aphp.fr)

Abstract

**BACKGROUND:** In the context of a rilpivirine/emtricitabine/tenofovir switch in HIV-1 infected patients with at least one year of virologic success, we determined whether proviral DNA is an alternative to plasma HIV-RNA for resistance genotyping.

**METHODS:** Resistance associated mutations (RAM) in DNA after at least one year of virologic success (viral load (VL) <50 copies/mL) were compared with those identified in the last plasma RNA genotype available. Rilpivirine/emtricitabine/tenofovir RAM studied were: K65R, L100I, K101E/P, E138A/G/K/R/Q, V179L, Y181C/I/V, M184V/I, Y188L, H221Y, F227C and M230I/L in reverse transcriptase. We studied patients without virologic failure (VF) and with  $\geq 1$  VF (two consecutive VL>50 copies/mL). Kappa's coefficient was used to measure agreement between the DNA and RNA genotypes.

**RESULTS:** In patients without (n=130) and with VF (n=114), RNA and DNA showed resistance to at least one drug of the rilpivirine/emtricitabine/tenofovir combination in 8% and 9% and in 60% and 45%, respectively. For rilpivirine RAM, correlation between RNA and DNA was higher in patients without VF than in patients with VF (kappa= 0.60 versus 0.19, p=0.026). Overall, prevalence of RAM was lower in DNA than in RNA.

**CONCLUSION:** The incomplete information provided by DNA genotypic test is more notable in patients with VF, suggesting that all resistance mutations associated with prior VF have not been archived in the proviral DNA or decreased to a level below threshold of detection. In the case where no historical plasma genotypic test is available, DNA testing might be useful to rule out switching to rilpivirine/emtricitabine/tenofovir.

## INTRODUCTION

The second generation NNRTI rilpivirine (RPV) formulated in a single tablet regimen (STR) with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) was approved by the European Medicines Agency and the US Food and Drug Administration as a once-daily oral treatment for adults infected with HIV-1 without mutations associated with resistance to TDF, FTC, or the NNRTI class, and harboring a viral load (VL)  $\leq 100\,000$  HIV-1 RNA copies/mL. Current antiretroviral treatment guidelines recommend switching therapy in virologically suppressed patients to improve adherence or tolerability or to allow for treatment simplification<sup>1-3</sup>. The SPIRIT study showed maintenance of virologic suppression at W48 for 89.3% of patients switching to rilpivirine/emtricitabine/tenofovir (RPV/FTC/TDF) from a ritonavir-boosted protease inhibitor (PI/r)-based regimen, compared with those who continued treatment with a PI/r regimen with a low risk of virologic failure (VF)<sup>4</sup>. A study demonstrated switching from efavirenz (EFV/FTC/TDF to RPV/FTC/TDF) was safe and effective for virologically suppressed HIV-infected patients with EFV intolerance<sup>5</sup>. Cohort studies have also shown efficacy and tolerability of switching to RPV/FTC/TDF<sup>6</sup>. Thus

RPV/FTC/TDF is considered as an appropriate therapy for switch for simplification in virologically suppressed HIV infected patient.

In this context, the use of previous plasma resistance genotypes was recommended to determine the susceptibility to this combination<sup>3</sup> because of the possible presence of pre-existing drug resistance mutations leading to VF. Studies have shown that resistance testing performed on HIV DNA lacks sensitivity compared with accumulated drug resistances from previous plasma genotypes.<sup>7,8</sup> However in patients fully virologically suppressed, the previous plasma genotypic test could be unavailable.

In the perspective of a switch to the combination RPV/TDF/FTC, the aim of this study was to determine whether proviral DNA is a potential relevant alternative to HIV-RNA for resistance genotyping in HIV-1 infected treated patients with at least one year of virologic suppression.

## MATERIAL and METHODS

In 244 HIV-1 infected patients treated in 2 centers (Nantes University Hospital and Pitié-Salpêtrière Hospital) with a prior available RNA resistance test, we retrospectively analyzed HIV DNA resistance genotype generated in PBMC after at least one year of virologic success (VL <50 copies/mL). Bulk sequences of the reverse transcriptase (RT) on RNA and DNA were determined using the ANRS consensus technique primer sequences described at <http://www.hivfrenchresistance.org>. We compared prevalence of HIV resistance mutations in the DNA and RNA genotype generated from the last detectable VL. We studied 2 groups of patients: 130 patients without previous VF (pre-therapeutic plasma genotype) and 114 patients with at least one previous VF (genotype on the more recent detectable VL)

regardless of the treatment they received (VF was defined as two consecutive VL>50 copies/mL).

RPV/TDF/FTC combination resistance mutations studied were defined according to the IAS list (K65R, K101E/P, E138A/G/K/R/Q, V179L, Y181C/I/V, M184V/I, Y188L, H221Y, F227C and M230I/L) in RT<sup>9</sup>. Resistance to RPV was defined according the ANRS <http://www.hivfrenchresistance.org/>. Kappa's coefficient was used to measure agreement between the DNA and RNA genotypes with values <0, 0.-0.2, 0.21-0.4, 0.41-0.6, 0.61-0.8, and 0.81-1.00 indicating no, very low, low, middle, high, and very high concordance, respectively.

We studied factors associated to the correlation between DNA and RNA mutations: VL, CD4 number at the time of both genotypes, number of treatment lines, number of previous VF and mean time between last plasma RNA genotype and proviral DNA genotype.

## RESULTS

We collected 244 pairs of DNA and RNA sequences for the RT gene (130 for patients without VF and 114 for patients with at least one VF). Characteristics of patients are presented in table 1. The mean time between last plasma RNA genotype and proviral DNA genotype was 46 and 37 months for patients without VF and with  $\geq 1$  VF, respectively. There are significant differences between the 2 groups for VL RNA ( $p \leq 0.0001$ ), numbers of lines of treatment ( $p \leq 0.0001$ ) and time between RNA and DNA genotypes ( $p = 0.0025$ ).

109 In patients without VF, the prevalence of studied resistance associated mutation (RAM) was  
110 very low in both RNA and DNA RT sequences (Figure 1a), with resistance to at least one drug  
111 of the RPV/FTC/FTC combination in 8.0% and 9.0%, respectively.

112 In patients with at least one prior VF, the prevalence of at least one RPV RAM was 24.6% and  
113 18.4 % in RNA and DNA genotype, respectively. The most prevalent RPV RAMs were  
114 Y181C/I/V (12.3%) and E138A/G/K/Q/R (7.8%) in RNA genotype; and in DNA,  
115 E138A/G/K/Q/R (7.9%) and M230I/L (6.1%) (Figure1b). Resistance to FTC and TDF was  
116 detected in 52.6% (M184V/I) and 0.9% (K65R) in RNA genotype and 37.7% (M184V/I) and  
117 0.9% (K65R) in DNA genotype. Resistance to at least one drug of the RPV/FTC/FTC  
118 combination was 60.0% in RNA and 45.0% in DNA.

119 In patients without VF, concordance between resistance in RNA and DNA was not  
120 significantly higher than in patients with VF (kappa= 0.57 versus 0.43 respectively,  $p=0.36$ ).

121 For RPV RAM, correlation between RNA and DNA was significantly higher in patients without  
122 VF than in patients with at least one VF (kappa= 0.60 versus 0.19 respectively,  $p=0.026$ ).

123 Overall, prevalence of rilpivirine associated mutations was lower in DNA than in RNA  
124 genotypic test, except for mutations at positions E138 and M230 that are APOBEC driven  
125 mutations (G to A) (Figure 1b). The factors associated with a good correlation between  
126 resistance according RNA and DNA genotype were a higher VL at RNA genotype ( $p=0.0124$ ),  
127 a shorter mean time between last plasma RNA genotype and proviral DNA genotype  
128 ( $p=0.0468$ ) and a higher number of treatment lines ( $p=0.0006$ ). Number of VF, subtypes, CD4  
129 at the time of RNA genotype or DNA genotype were not associated with correlation of  
130 resistance in RNA and DNA.

131

## DISCUSSION

In the context of switch to RPV/TDF/FTC therapy in HIV-1 infected treated patients, this study shows a good concordance between DNA and RNA genotypes in patients without prior VF and who are successfully suppressed for at least one year. However, DNA genotype is less informative than RNA genotype in patients with at least one prior VF. The good concordance in patients with no prior VF is in accordance with results of studies on naive patients showing that DNA genotype could be useful and even more informative than standard RNA genotyping<sup>10,11</sup>.

In patients with at least one prior VF, the rate of selected resistance associated mutations to RPV in RNA was somewhat lower than in previous studies conducted in patients pre-exposed to an NNRTI-based regimen but naive to RPV<sup>12-14</sup>. Indeed, in our study the 3 main RPV RAMs at codons 181, 101 and 138 had a frequency of 12.3, 2.6 and 5.3% versus 18 to 22.6%, 7 to 20.5% and 5.3 to 14% in these 3 studies, respectively. This lower frequency could be due to the fact that our studied population not exclusively contained NNRTI failing patients, nevertheless the 3 main RPV RAM are similar to those observed in others studies. In the HIV DNA, we showed a lower prevalence of the RPV RAM: 101, 181 and 221 with 0.9%, 3.5% and 0.9% versus 7%, 18% and 4% in the study of Gallien et al<sup>12</sup>. However, patients of this study were selected to have a prior VF especially to NVP or EFV and had a prior history of triple class failure.

In patients with prior VF, our study generally confirmed results of previous studies on the discordance between DNA and RNA genotypes. Indeed, in a large number of patients with undetectable or low VL under treatment, a study showed a concordance between DNA and RNA of 26.3% for NNRTI mutations<sup>7</sup>. Another study demonstrated that mutations conferring

resistance to at least one antiretroviral drug were detected exclusively by RNA genotyping or exclusively by DNA genotyping in 47% and 1% of patients for NNRTIs, respectively<sup>8</sup>.

Overall, prevalence of RAM was generally lower in DNA than in RNA genotypic tests, except for mutations at positions E138 and M230 that are APOBEC driven mutations. Indeed, APOBEC induces G to A viral mutation and this mechanism could explain the persistence of mutations in archived cellular proviral DNA<sup>15</sup>.

The incomplete information provided by the DNA test is more notable in patients with at least one prior VF, suggesting that all resistance mutations associated with the prior VF may not have been archived in the proviral DNA or not detected with classical Sanger sequencing. A good correlation between prior RNA genotype and current DNA genotype was significantly associated with a higher VL at RNA genotype and a shorter mean time between last plasma RNA and proviral DNA genotype. This suggest that DNA genotypic testing, with current techniques, might be suboptimal in case of low intracellular VL of resistant viruses and that archived resistant viruses might decrease over time. Further studies would be warranted to explore the interest of Ultra Deep Sequencing on DNA and the clinical relevance of minority variants.

From a clinical perspective, we recommend that before switching to RPV/TDF/FTC, one takes into consideration full treatment history and available past plasma genotypic testing, and in the absence of prior plasma genotype, avoid use of RPV/TDF/FTC if RAM to this combination are detected using a DNA genotype in a virologically suppressed patient.

## **Acknowledgements**



177 We thank G. Le Mallier and P. Grange for their technical assistance.

## 178 **Funding section**

179 This work was supported by the Agence Nationale de Recherches sur le SIDA (ANRS).

## 180 **Transparency declarations**

181 F. R. has received honoraria for advisories or invited talks or conferences and research grants  
182 from Abbvie Labs, Bristol-Myers Squibb, Gilead Sciences, Merck Laboratories, MSD, Janssen  
183 Pharmaceuticals and ViiV Healthcare. A. G. M. has received honoraria for advisories or  
184 invited talks or conferences and research grants from Abbvie Labs, Bristol-Myers Squibb,  
185 Gilead Sciences, Merck Laboratories, MSD, Janssen Pharmaceuticals and ViiV Healthcare. V.  
186 C. has received honoraria for advisories or invited talks or conferences and research grants  
187 from Abbvie Labs, Bristol-Myers Squibb, Gilead Sciences, Merck Laboratories, MSD, Janssen  
188 Pharmaceuticals and ViiV Healthcare. The other authors have none to declare.

189

190

## 191 **REFERENCES**

192 1. Guidelines-7.1-english.pdf. Available at: [http://www.eacsociety.org/files/guidelines-7.1-](http://www.eacsociety.org/files/guidelines-7.1-english.pdf)  
193 [english.pdf](http://www.eacsociety.org/files/guidelines-7.1-english.pdf).

194 2. HIV/AIDS Guidelines - adultandadolescentgl.pdf. Available at:  
195 <https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf>.

196 3. Rapport\_Morlat\_2013\_Mise\_en\_ligne.pdf. Available at:  
197 [http://www.sante.gouv.fr/IMG/pdf/Rapport\\_Morlat\\_2013\\_Mise\\_en\\_ligne.pdf](http://www.sante.gouv.fr/IMG/pdf/Rapport_Morlat_2013_Mise_en_ligne.pdf).

198 4. Palella FJ, Fisher M, Tebas P, *et al*. Simplification to rilpivirine/emtricitabine/tenofovir  
199 disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a  
200 randomized trial of HIV-1 RNA-suppressed participants. *AIDS Lond Engl* 2014; **28**: 335–44.

5. Mills AM, Cohen C, Dejesus E, *et al.* Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. *HIV Clin Trials* 2013; **14**: 216–23.

6. Cazanave C, Reigadas S, Mazubert C, *et al.* Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012–2014. *Open Forum Infect Dis* 2015

7. Wirlden M, Soulie C, Valantin M-A, *et al.* Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia. *J Antimicrob Chemother* 2011; **66**: 709–12.

8. Delaugerre C, Braun J, Charreau I, *et al.* Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication. *HIV Med* 2012; **13**: 517–25.

9. Complera\_pi.pdf. Available at:  
[http://www.gilead.com/~media/files/pdfs/medicines/hiv/complera/complera\\_pi.pdf?la=en](http://www.gilead.com/~media/files/pdfs/medicines/hiv/complera/complera_pi.pdf?la=en)

10. Ellis GM, Page LC, Burman BE, Buskin S, Frenkel LM. Increased detection of HIV-1 drug resistance at time of diagnosis by testing viral DNA with a sensitive assay. *J Acquir Immune Defic Syndr* 1999 2009; **51**: 283–9.

11. Kabamba-Mukadi B, Duquenne A, Henrivaux P, *et al.* HIV-1 proviral resistance mutations: usefulness in clinical practice. *HIV Med* 2010; **11**: 483–92.

12. Gallien S, Charreau I, Nere ML, *et al.* Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine. *J Antimicrob Chemother* 2015; **70**: 562–5.

13. Anta L, Llibre JM, Poveda E, *et al.* Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. *AIDS Lond Engl* 2013; **27**: 81–5.

14. Lambert-Niclot S, Charpentier C, Storto A, *et al.* Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naïve patients failing antiretroviral therapy. *J Antimicrob Chemother* 2014; **69**: 1086–9.

15. Mulder LCF, Harari A, Simon V. Cytidine deamination induced HIV-1 drug resistance. *Proc Natl Acad Sci U S A* 2008; **105**: 5501–6.

**Table 1:** Characteristics of patients according the 2 groups: without previous virologic failure (VF) and patients with  $\geq 1$  VF. \*corresponding to pretreatment VL for patients without previous VF and VL at failure for patients with at least one VF

	<b>Without VF N=130 Median (standard deviation)</b>	<b>With at least one VF N=114 Median (standard deviation)</b>
<b>VL RNA log copies/mL*</b>	4.5 (1.2)	3.0 (1.1)
<b>CD4 at time of RNA genotype Number of cells/mm<sup>3</sup></b>	347 (230.2)	358 (251.6)
<b>CD4 at time of DNA genotype Number of cells/mm<sup>3</sup></b>	586 (311.6)	537 (338.2)
<b>Time between RNA and DNA genotypes (month)</b>	43 (31)	29.5 (36.8)
<b>Number of lines of treatment</b>	3 (3.3)	12 (7.5)

Figure 1 : Prevalence of resistance mutations to RPV/TDF/FTC in RNA and in DNA : a) in patients without previous virologic failure. b) in patients with at least one virologic failure.\* correspond to statistical significant difference of prevalence of resistance mutations between DNA and RNA ( $p < 0.05$ )

a)

